doxorubicin

• 分子结构分类: 有机化合物 - 苯类化合物 - 并四苯
• 英文名称: doxorubicin
• 英文别名: adriamycin；(7S,9R)-7-[[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]methyl]-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
• 化学式: C₂₈H₃₁NO₁₀
• 分子量: 541.555
• InChiKey: BDQGBTQOTZLQGP-QMRBUBMQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  39
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  197
• 氢给体数：
  6
• 氢受体数：
  11

反应信息

• 作为反应物：
  描述：

  β-(4-carboxybutyryl)cobalamin 、 doxorubicin 在 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 三乙胺 作用下， 以 二甲基亚砜 为溶剂， 反应 18.0h， 以83%的产率得到
  参考文献：
  名称：

  使用荧光团作为光捕获天线对光响应化合物进行可调谐的可见光和近红外光活化

  摘要：

  尽管维生素 B 12的 corrin 环无法有效吸收 550 nm 以上的光，但表明市售荧光团可用作天线来捕获长波长光，以促进波长高达 800的 Co  C 键断裂纳米。利用长可见光和近红外光控制生物活性物质分子特性的能力对药物递送、纳米技术和细胞行为的时空控制具有重要意义。

  DOI：

  10.1002/anie.201308816

文献信息

• Binding molecules and methods of use thereof
  申请人：Cuervo H. Julio

  公开号：US20070248988A1

  公开（公告）日：2007-10-25

  Binding molecules are described.
• CHEMOTHERAPEUTIC-RELEASING IMPLANTABLE STICK, METHODS OF MANUFACTURE AND PRECURSOR MATERIALS
  申请人：The Johns Hopkins University

  公开号：US20190231802A1

  公开（公告）日：2019-08-01

  A chemotherapeutic-releasing implantable stick is described herein. The chemotherapeutic-releasing implantable stick includes an implantable stick having a length and thickness to fit within a needle track from a needle biopsy, the implantable stick providing a biocompatible and biodegradable substrate for the release of a chemotherapeutic agent when implanted. The chemotherapeutic-releasing implantable stick further includes a chemotherapeutic agent absorbed into the implantable stick.
• LIPOSOMAL ANTICANCER COMPOSITIONS
  申请人：IriSys, LLC

  公开号：US20210205245A1

  公开（公告）日：2021-07-08

  Provided herein includes methods and compositions for the treatment of cancer. Described herein are liposome encapsulated chemotherapeutic agents and methods for preparing and utilizing the same.
• COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING CANCER AND IMMUNOLOGICAL DISORDERS
  申请人：IL-2RX, Inc.

  公开号：US20210252160A1

  公开（公告）日：2021-08-19

  The present disclosure provides novel polypeptide-therapeutic compound or hormone-therapeutic compound conjugates using cleavable or non-cleavable linkers, whereby the polypeptide or hormone serves to target specific cells using receptor expression on the targeted cell to bind the ligand (polypeptide or hormone) carrying the therapeutic compound unlike antibody drug conjugates. Upon binding, the ligand and the therapeutic compound (multiples of the therapeutic compound in some embodiments) enter the cell by receptor-mediated endocytosis, and release drugs conjugated to the ligand by linkers, to interact with intracellular components to enhance, restore, or block a signal transduction process. The ligands for the polypeptide-therapeutic compound or hormone-therapeutic compound conjugates include, but are not limited to: cytokines, growth factors and hormones among other proteins with corresponding cell surface specific receptors. The disorders targeted by such polypeptide-therapeutic compound or hormone-therapeutic compound conjugates include, but are not limited to: immunological disorders (e.g., allergy and autoimmune disorders) and cancer.